Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10340280 | 0.97 | HDAC1 (0.47) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL1752117 | 0.93 | ALDH1A1 (0.48) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| Hydrogen Sulfide SCHEMBL20305480 | 0.92 | ALDH1A1 (0.47) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL2002797 | 0.88 | ALDH1A1 (0.49) | ALDH1A1PKMMAPTKMT2A | |
| SCHEMBL327593 | 0.86 | HPGD (0.44) | ALDH1A1PKMHDAC1HDAC2HDAC4 | |
| SCHEMBL44725 | 0.86 | ALDH1A1 (0.50) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL10340551 | 0.84 | ALDH1A1 (0.43) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL21768790 | 0.83 | ALDH1A1 (0.51) | ALDH1A1PKMMAPTKMT2A | |
| SCHEMBL28630260 | 0.81 | HDAC1 (0.41) | ALDH1A1PKMHDAC1HDAC2 | |
| SCHEMBL616908 | 0.79 | ALDH1A1 (0.54) | ALDH1A1PKMMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020033851-A1 | COMPOSITIONS COMPRISING PRIMING AGENTS AND THEIR USE IN THE TREATMENT OF CANCER | Notable Labs, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20200046737-A1 | METHODS FOR TREATING CANCER, AND COMPOSITIONS THEREFOR | NOTABLE LABS INC (US) | 2020-02-13 | — | — | US | disclosed |
| EP-1819359-B1 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS OF THEIR PRODUCTION AND THEIR USE | JANSSEN BIOTECH INC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8834920-B2 | Liposome composition for targeting egfr receptor | ALZA CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8603483-B2 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8536113-B2 | EGFR binding peptides and uses thereof | JANSSEN BIOTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8278415-B2 | Dimeric high affinity EGFR constructs and uses thereof | CENTOCOR, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120213844-A1 | LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR | HUANG KEN SHI KUN (US) | 2012-08-23 | — | — | US | disclosed |
| US-20100151003-A1 | EGFR BINDING PEPTIDES AND USES THEREOF | JANSSEN BIOTECH, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100098681-A1 | DIMERIC HIGH AFFINITY EGFR CONSTRUCTS AND USES THEREOF | WANG BRYAN | 2010-04-22 | — | — | US | disclosed |
| WO-2004018000-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMONOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1391213-A1 | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents | Boehringer Ingelheim International GmbH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | disclosed |
| US-5395924-A | Oligosaccharide or glycopeptide bound to lectin and conjugated with cell binding agent, improved targeting of cells for cytolysis | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5239062-A | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0196007-B1 | DESMOSINE DERIVATIVES AND REAGENT FOR PREPARING ARTIFICIAL ANTIGENS | JAPAN TOBACCO INC. (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4841055-A | Desmosine derivatives and reagent for preparing artificial antigens | JAPAN TOBACCO INC. (JP) | 1989-06-20 | — | — | US | disclosed |
| US-4723012-A | Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same | JAPAN TOBACCO INC. (JP) | 1988-02-02 | — | — | US | disclosed |
| EP-0196007-A2 | Desmosine derivatives and reagent for preparing artificial antigens | JAPAN TOBACCO INC. (JP) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | ALDH1A1 178/4885PKM 4656/4885HDAC1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.